Mayo Clinic researchers have discovered an enzyme they say is tightly linked to how aggressive pancreatic cancer will be in a patient.
It also offers a number of possible future clinical advances, such as a way to gauge outcome in individual patients, and insight into potential therapy to shut down activity of the enzyme, known as Rac1b.
"The implication from our research is that Rac1b is activating unique pathways in pancreatic tumors that make this cancer aggressive. If we can therapeutically target that pathway, we may be able to have an impact on this very difficult-to-treat disease," says the study's senior investigator, Derek Radisky, Ph.D., a researcher with the Mayo Clinic Cancer Center in Jacksonville, Fla.
A potential drug target would have to be found within the cancer-causing pathways activated by Rac1b, since the enzyme is difficult to target because it is involved in many normal biological processes, Dr. Radisky says. He and his colleagues are now working to uncover how Rac1b ramps up pancreatic cancer progression.
The RAC1 superfamily of proteins — which play important regulatory roles in cell growth and cell movement — have been implicated in other cancers, such as melanoma and non-small cell lung cancer, but before this study, no one knew that one sub-form, Rac1b, played a role in pancreatic cancer.
The research team includes investigators from Mayo Clinic in Florida and Mayo Clinic SPORE in Pancreatic Cancer, one of three cancer centers in the U.S. to receive a Specialized Program of Research Excellence (SPORE) grant for pancreatic cancer from the National Cancer Institute. The Pancreatic Cancer SPORE is specifically committed to reducing the incidence and mortality of pancreatic cancer. The team began their research by investigating why pancreatic cancer cells produce matrix metalloproteinases (MMPs), enzymes that break down the sticky adhesion molecules that keep cells glued together in a tissue, or in a tumor. MMPs allow cancer cells to migrate away from a tumor.
"Most MMPs are made by cells that surround and support a tumor, not by the tumor itself, as we see in pancreatic cancer," Dr. Radisky says.
Using a combination of human tissue biopsies, novel transgenic animal models and cell culture studies, the researchers established a link between expression of MMP3 and activation of Rac1b. Then, using Mayo Clinic's large panel of human pancreatic cancer biopsies, the scientists found that expression levels of Rac1b were significantly associated with the cancer's prognosis.
The researchers verified their findings by treating cultured pancreatic cancer cells with recombinant MMP3. They found this was sufficient to induce Rac1b and increased cancer invasiveness.
"Pancreatic cancer is not uniformly aggressive — some patients have a relatively better outcome. This work allows us to hone in on those patients who don't do as well, and who would most benefit from more targeted therapies," Dr. Radisky says.
The study was supported by the National Cancer Institute (CA122086, CA154387, R01CA159222 and R01CA136754), and by the Mayo Clinic SPORE in Pancreatic Cancer (P50 CA102701).
About Mayo Clinic
Recognizing 150 years of serving humanity in 2014, Mayo Clinic is a nonprofit worldwide leader in medical care, research and education for people from all walks of life. For more information, visit 150years.mayoclinic.org, MayoClinic.org or newsnetwork.mayoclinic.org/.
Kevin Punsky | idw - Informationsdienst Wissenschaft
Penn study identifies viral product that promotes immune defense against RSV
04.09.2015 | University of Pennsylvania
Columbia Engineering team develops targeted drug delivery to lung
03.09.2015 | Columbia University School of Engineering and Applied Science
In a survey of NASA's Hubble Space Telescope images of 2,753 young, blue star clusters in the neighboring Andromeda galaxy (M31), astronomers have found that M31 and our own galaxy have a similar percentage of newborn stars based on mass.
By nailing down what percentage of stars have a particular mass within a cluster, or the Initial Mass Function (IMF), scientists can better interpret the light...
Researchers at the Fraunhofer Institute for Solar Energy Systems ISE have developed a highly compact and efficient inverter for use in uninterruptible power...
China's Loess Plateau was formed by wind alternately depositing dust or removing dust over the last 2.6 million years, according to a new report from University of Arizona geoscientists. The study is the first to explain how the steep-fronted plateau formed.
China's Loess Plateau was formed by wind alternately depositing dust or removing dust over the last 2.6 million years, according to a new report from...
The leaves of the lotus flower, and other natural surfaces that repel water and dirt, have been the model for many types of engineered liquid-repelling surfaces. As slippery as these surfaces are, however, tiny water droplets still stick to them. Now, Penn State researchers have developed nano/micro-textured, highly slippery surfaces able to outperform these naturally inspired coatings, particularly when the water is a vapor or tiny droplets.
Enhancing the mobility of liquid droplets on rough surfaces could improve condensation heat transfer for power-plant heat exchangers, create more efficient...
Longer, more severe, and hotter droughts and a myriad of other threats, including diseases and more extensive and severe wildfires, are threatening to transform some of the world's temperate forests, a new study published in Science has found. Without informed management, some forests could convert to shrublands or grasslands within the coming decades.
"While we have been trying to manage for resilience of 20th century conditions, we realize now that we must prepare for transformations and attempt to ease...
03.09.2015 | Event News
20.08.2015 | Event News
20.08.2015 | Event News
04.09.2015 | Power and Electrical Engineering
04.09.2015 | Machine Engineering
04.09.2015 | Materials Sciences